November 24th 2021, 9:01pm
All-trans retinoic acid and arsenic trioxide used together can let children avoid treatment with convention chemotherapy, which has more adverse effects.
November 20th 2021, 12:40pm
Although acute promyelocytic leukemia is highly treatable in early stages, the medication needed stop hematologic emergencies, all-trans retinoic acid, is often not available, a new study says.
November 16th 2021, 8:45pm
Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.
November 13th 2021, 3:30pm
A safety analysis of 6 trials found zanubrutinib has a toxicity profile consistent wth other Bruton tyrosine kinase (BTK) inhibitors.
November 13th 2021, 11:45am
November 5th 2021, 7:15pm
Posters presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting analyzed patient and physician perspectives on blood transfusions in acute myeloid leukemia (AML).
November 3rd 2021, 4:07pm
Two analyses presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting highlighted the safety and cost benefits of tazemetostat compared with phosphoinositide 3 (PI3) kinase inhibitors for patients with follicular lymphoma.
October 30th 2021, 7:30pm
Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.
October 25th 2021, 8:30pm
Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.
October 22nd 2021, 1:45pm
Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib.
